溴隐亭对肢端肥大症患者胰岛素分泌及糖耐量的影响。

The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly.

作者信息

Feek C M, Bevan J S, Taylor S, Brown N S, Baird J D

出版信息

Clin Endocrinol (Oxf). 1981 Nov;15(5):473-8. doi: 10.1111/j.1365-2265.1981.tb00690.x.

DOI:10.1111/j.1365-2265.1981.tb00690.x

Abstract

The oral administration of bromocriptine 5 mg 6-hourly to twelve patients with acromegaly for a mean period of 12 (range 3-27) months significantly reduced whole blood glucose, plasma insulin and plasma growth hormone (GH) concentrations during a 50 g oral glucose tolerance test (OGTT). After this period of treatment, bromocriptine was withdrawn for 48 h resulting in a significant rise in whole blood glucose, plasma insulin and plasma GH concentrations during a repeat OGTT. It is concluded that bromocriptine therapy improves glucose tolerance in acromegaly by suppressing GH secretion and consequently GH-mediated antagonism of insulin.

摘要

对12例肢端肥大症患者每6小时口服5毫克溴隐亭，平均治疗12个月（范围3 - 27个月），在50克口服葡萄糖耐量试验（OGTT）期间，全血葡萄糖、血浆胰岛素和血浆生长激素（GH）浓度显著降低。经过这段治疗期后，停用溴隐亭48小时，在重复的OGTT期间，全血葡萄糖、血浆胰岛素和血浆GH浓度显著升高。结论是，溴隐亭治疗通过抑制GH分泌，从而改善GH介导的胰岛素拮抗作用，提高肢端肥大症患者的葡萄糖耐量。